BPC-157

BPC-157 10 mg is a synthetic pentadecapeptide — a 15-amino-acid chain with the sequence GEPPPGKPADDAGLV (CAS 137525-51-0, molecular weight approximately 1419 Da). It ships as a lyophilized powder in a sealed, light-protected vial with a printed lot number for full batch traceability. Each unit is supplied with general handling information for laboratory storage and reconstitution, intended for qualified researchers working under appropriate laboratory conditions.

BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence identified in a gastric protective protein. It is not itself a naturally circulating human hormone. Preclinical research — extensive across in-vitro and rodent models — has investigated its interaction with angiogenesis pathways, fibroblast migration, and nitric-oxide signaling, primarily in gut, tendon, and ligament injury models. Human evidence remains limited by comparison. FDA's July 2026 briefing document identified five published human studies involving roughly 80 total participants, with no study extending treatment beyond two weeks. A 2025 systematic review focused specifically on orthopedic sports medicine, using narrower inclusion criteria, identified only one qualifying human study among the 36 it reviewed. No randomized controlled trial of BPC-157 has been completed. A Phase 2 randomized, placebo-controlled trial in acute hamstring strain (NCT07437547) is currently recruiting, with no results posted to date. These findings describe laboratory and preclinical research directions only. They are not evidence of safety or effectiveness for human or animal use.

Each batch of BPC-157 10 mg undergoes third-party HPLC testing, which separates and quantifies the compound to establish chromatographic purity, and mass spectrometry, which confirms molecular identity by mass. A Certificate of Analysis (COA) is issued for the specific lot number shipped, documenting purity and batch-level results. Testing establishes product identity and purity — it does not establish clinical safety or effectiveness for any use.

BPC-157 10 mg is sold strictly for laboratory and research use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic product. It has not been evaluated by the FDA and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any condition. BPC-157 is not FDA-approved for any use. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 free base and acetate for potential inclusion on the Section 503A Bulks List; this recommendation is advisory only and went against FDA staff's own proposal. As of this writing, BPC-157 is not on the 503A Bulks List, no final FDA rule has been issued, and it is not legally compoundable under Section 503A.